SCHEMBL1379463

SCHEMBL1379463

Nc1onc2cccc(-c3ccc(NC(=O)Nc4ccc(OC(F)(F)F)cc4)cc3)c12

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDR P35968 16/20 0.71
KIT P10721 15/20 0.71
FLT3 P36888 12/20 0.71
ABL1 P00519 1/20 0.61
LCK P06239 1/20 0.61
FYN P06241 1/20 0.61
CSF1R P07333 1/20 0.61
LYN P07948 1/20 0.61
SRC P12931 1/20 0.61
FLT1 P17948 1/20 0.61
FLT4 P35916 1/20 0.61
BLK P51451 1/20 0.61
EPHX2 P34913 1/20 0.52
PDGFRB P09619 1/20 0.48
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4786678 0.87 KDR (0.74) KDRKITFLT3ABL1LCK
SCHEMBL1381023 0.86 KDR (0.70) KDRKITFLT3ABL1LCK
SCHEMBL4737823 0.86 KDR (0.70) KDRKITFLT3CSF1RFLT1
SCHEMBL1382612 0.85 KDR (0.68) KDRKITFLT3ABL1LCK
SCHEMBL1383101 0.84 KDR (0.67) KDRKITFLT3ABL1LCK
SCHEMBL420478 0.83 KIT (1.00) KDRKITFLT3ABL1LCK
SCHEMBL4739581 0.83 KDR (0.62) KDRKITFLT3ABL1LCK
SCHEMBL4736486 0.82 KDR (0.72) KDRKITFLT3ABL1LCK
SCHEMBL4737316 0.82 KDR (0.68) KDRKITFLT3ABL1LCK
SCHEMBL4735263 0.82 KDR (0.70) KDRKITFLT3ABL1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4810427-B2 2011-11-09 JP claimed
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed
EP-1638941-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-03-29 EP claimed
WO-2004113304-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-12-29 WO claimed
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO disclosed